Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patientsSARS-CoV-2에 대한 중화 항체 반응은 경증 및 무증상 환자에서 증상 발병 후 9개월 동안 지속됩니다.Article Published on 2021-11-012022-09-12 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome Adults analysed Antibody Response asymptomatic patient Charles de Gaulle Cohort collected coronavirus disease Coronavirus-2 COVID-19 Critical disease severity exhibited French General population immune response immunocompetent adults infected with COVID-19 Infection Mild Neutralizing activity Neutralizing antibodies neutralizing antibody outbreak Patient performed persist persistence positive serology predict primary care PSO quarantine Sample SARS-CoV-2 SARS-COV-2 infection seroconversion rate serological results serology serum serum sample symptom onset tested Vaccination strategy [DOI] 10.1016/j.ijid.2021.09.002 PMC 바로가기 [Article Type] Article
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations단일 클론 항체 조합에 의한 SARS-CoV-2 변이체 전반의 저용량 생체 내 보호 및 중화Article Published on 2021-10-292022-09-10 Journal: Nature Immunology [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered angiotensin angiotensin-converting enzyme 2 antibodies antibody Antimicrobial responses clearance Combination combinations complementary coronavirus Coverage cross-neutralizing demonstrated Effect escape mutants F486 function functions identify in vivo low-dose mAb mAb cocktail mAbs mechanism monoclonal antibodies monoclonal antibody monoclonal antibody combination N-terminal domain neutralization Neutralizing activity Neutralizing antibodies neutralizing antibody NTD prevented prevention PROTECT provided RBD Receptor-binding domain recognize residue respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 variant severe acute respiratory syndrome Coronavirus spike glycoprotein Spike protein target the RBD the receptor-binding domain the spike protein therapeutic These data unique variants variants of concern Viral viral escape viral inactivation viral infection viral neutralization vulnerability [DOI] 10.1038/s41590-021-01068-z PMC 바로가기 [Article Type] Article
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High PotencyImmunology Published on 2021-10-262022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] B.1.1.7 B.1.167.2 B.1.351 Beta binding efficiency Blot Cell characterization characterized concern conformational contribute convalescent sera COVID-19 Delta Delta VOC Diagnosis Efficacy epitope epitopes expression Escherichia coli expressed flow cytometry full-length spike protein functional Gamma glycosylated HEK293T cell immunoprecipitation inhibit initial lentivirus mAb mAbs majority mammalian mice immunization monoclonal antibody mouse Mutation NAb neutralization Neutralizing activity neutralizing antibody neutralizing monoclonal antibodies P.1 Pathogenesis plaque-reduction neutralization test potency produced Protein pseudotyped RBD reduction reference sequence response rRBD SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RBD SARS-CoV-2 spike glycoprotein SARS-CoV-2 variant SARS-CoV-2 variants Spike protein suggested supernatant the RBD the SARS-CoV-2 therapy transmembrane Vaccine variants of concern VoC Wuhan [DOI] 10.3389/fimmu.2021.750386 PMC 바로가기 [Article Type] Immunology
Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and LambdaSARS-CoV-2 변이체 카파, 델타 및 람다에 의한 밤라니비맙 내성의 구조-기능 분석Article Published on 2021-10-252022-09-11 Journal: Journal of Chemical Information and Modeling [Category] SARS, 변종, [키워드] ACE2 Affect angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibodies antibody bamlanivimab binding binding affinity carried characterized Contact contact with crystal structures Delta demonstrated direct contact Effects evade experiment host cells L452R Lambda LY-CoV555 molecular molecular dynamics molecular mechanism mutant Mutation Neutralization assay neutralization assays Neutralizing Neutralizing activity Patient pseudovirions RBD RBDs Receptor binding domain receptor binding domains reduce residue resistance SARS-CoV-2 SARS-CoV-2 variant significantly Spike proteins the binding affinity the RBD therapeutic Treatment variant variants viral entry wild-type SARS-CoV-2 [DOI] 10.1021/acs.jcim.1c01058 PMC 바로가기 [Article Type] Article
Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening단일 B 세포 스크리닝을 통한 고친 화성, 강력한 SARS-COV-2 중화 항체의 발견 및 특성Article Published on 2021-10-202022-09-01 Journal: Scientific Reports [Category] MERS, SARS, 진단, [키워드] ACE2 antibodies antibody Antibody generation antibody repertoire Applied immunology binding biologics coronavirus disease COVID-19 Critical Diagnosis Diseases high affinity highlight IgG1 immunized mice Infectious disease Infectious diseases Intervention Isolation memory B cells monoclonal antibodies Neutralizing activity Neutralizing antibodies neutralizing antibody Novel coronavirus novel coronavirus disease Prophylactic Rapid Receptor-binding domain SARS-CoV-2 SARS-CoV-2 neutralizing antibody single B cell Strategy the receptor-binding domain Treatment valency was used [DOI] 10.1038/s41598-021-99401-x PMC 바로가기 [Article Type] Article
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post–COVID-19 Convalescent Samples전염병 전 및 코로나19 이후 회복기 샘플에서 SARS-CoV-2에 대한 혈청 교차 반응성 항체 및 기억 반응 검출Major Articles and Brief Reports Published on 2021-10-152022-09-10 Journal: The Journal of Infectious Diseases [Category] MERS, SARS, 진단, 치료기술, 치료법, [키워드] 19 2 Activation acute respiratory syndrome acute respiratory syndrome coronavirus Adults Anti-S1 anti–SARS-CoV-2 IgG antibody antibodies antibody Antibody titer Antibody titers antigens children collected common human coronavirus (HCoV)-HKU1 convalescent COVID-19 patient convalescent COVID-19 patients coronavirus coronavirus disease Coronavirus disease 2019 correlated CoV COVID COVID-19 cross cross-reactive cross-reactive antibody demonstrated detectable detection domain effective Endemic endemic human coronavirus endemic human coronaviruses enzyme enzyme-linked immunosorbent assays HCoV HCoVs HKU1 IgG antibodies Immunity Immunological memory increase Infection investigated lead less memory response Neutralization assay Neutralizing activity NL63 notable novel coronaviruses nucleocapsid protein OC43 Promoting proportion reactive immunity respiratory response Result Sample SARS SARS-CoV-2 SARS-CoV-2 pseudotyped virus SARS-CoV-2 S1 sera serum antibody serum sample serum samples severe disease susceptible β-coronavirus β-Coronaviruses [DOI] 10.1093/infdis/jiab333 PMC 바로가기 [Article Type] Major Articles and Brief Reports
Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43Article Published on 2021-10-142022-10-28 Journal: Viruses [Category] Coronavirus, MERS, [키워드] antibody Antibody neutralization betacoronaviruses bind Cell children cross-neutralization Cytopathic effect described develop ELISA human coronavirus Human monoclonal antibody Human plasma Humoral response In vitro assay infected cells Infection Live virus measure monoclonal antibody Mortality neutralization assays neutralize Neutralizing activity Neutralizing antibodies OC43 recipients respiratory viral infection respiratory viral infections the spike protein viral neutralization [DOI] 10.3390/v13102075 PMC 바로가기 [Article Type] Article
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controlsLetter to the Editor Published on 2021-10-132022-10-29 Journal: Journal of Hematology & Oncology [Category] COVID-19, MERS, SARS, [키워드] analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies antibody BNT162b2 vaccine conserved Control controls COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccine daratumumab form healthy control high risk humoral IgG level mRNA vaccine Multiple Multiple myeloma neutralization Neutralizing activity Patient potential risk proportion response SARS-CoV-2 second dose supplementary material Treatment uncontrolled disease Vaccine [DOI] 10.1186/s13045-021-01183-2 PMC 바로가기 [Article Type] Letter to the Editor
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding DomainSARS-CoV-2 스파이크 단백질 수용체 결합 도메인에 특이적인 인간 중화 항체의 구조적 기초Research Article Published on 2021-10-132022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 acute respiratory syndrome coronavirus-2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibodies antibody Antigen assist B cell B.1.1.7 back Basis bind binding caused complex conformation convalescent coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 pandemic crystal structure domain dominant drug drug candidate drug candidates drugs Economy effective Epitopes global health Health Human human Angiotensin-converting enzyme in vivo Intervention Lineage Lineage B.1.1.7 mAbs mechanism monoclonal antibodies monoclonal antibody Mutagenesis mutant NAbs native human monoclonal antibody Neutralizing activity neutralizing antibody neutralizing effect neutralizing epitope neutralizing monoclonal antibodies neutralizing monoclonal antibody New coronavirus not affect Prophylactic prophylactic and therapeutic efficacies RBD RBS-C receptor Receptor-binding domain Research residue respiratory Respiratory disease responsible reveal ridge S-RBD Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Specific spike Spike protein the SARS-CoV-2 the spike protein Therapeutic antibody therapeutic efficacy Transgenic mouse understanding Vaccine Vaccine development variety [DOI] 10.1128/Spectrum.01352-21 PMC 바로가기 [Article Type] Research Article
The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) VaccinesImmunology Published on 2021-10-122022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] adverse effect Antibody Response Blood booster characterized clinical collected CoronaVac dominant Effect Effects elicit epithelial lining exhibited first dose IgA IgG IgG response Immunity Immunoglobulin immunoglobulin A Immunoglobulin G Immunological response inactivated Inactivated virus vaccine induce mRNA mRNA vaccine mucosal mucosal immunity nasal nasal epithelial lining fluid neutralization Neutralizing Neutralizing activity neutralizing effect novel objective other tissue plasma plasma antibody plasma sample quantified recipient response responses Result SARS-CoV-2 SARS-CoV-2 S1 protein SARS-CoV-2 vaccine serological serological immunity subject subjects vaccination Vaccine virus widespread [DOI] 10.3389/fimmu.2021.744887 PMC 바로가기 [Article Type] Immunology